Toyota|$17.69 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.10 (¥4,333)+1.21%▲ (in JPY terms)
SoftBank|$22.53 (¥3,602)-3.64%▼ (in JPY terms)
MUFG|$21.94 (¥3,508)+0.29%▲ (in JPY terms)
Keyence|$469.50 (¥75,070)+0.05%▲ (in JPY terms)
Nintendo|$53.94 (¥8,624)+0.71%▲ (in JPY terms)
NTT|$1.04 (¥167)-0.36%▼ (in JPY terms)
Takeda|$42.83 (¥6,848)+0.34%▲ (in JPY terms)
Tokyo Electron|$59.51 (¥9,516)+2.28%▲ (in JPY terms)
Recruit|$109.92 (¥17,575)+5.15%▲ (in JPY terms)
ITOCHU|$15.09 (¥2,413)+0.02%▲ (in JPY terms)
Honda|$11.43 (¥1,828)+0.91%▲ (in JPY terms)
Shin-Etsu|$35.91 (¥5,742)-0.85%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.57%▲ (in JPY terms)
Fast Retailing|$510.40 (¥81,610)+1.77%▲ (in JPY terms)
Toyota|$17.69 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.10 (¥4,333)+1.21%▲ (in JPY terms)
SoftBank|$22.53 (¥3,602)-3.64%▼ (in JPY terms)
MUFG|$21.94 (¥3,508)+0.29%▲ (in JPY terms)
Keyence|$469.50 (¥75,070)+0.05%▲ (in JPY terms)
Nintendo|$53.94 (¥8,624)+0.71%▲ (in JPY terms)
NTT|$1.04 (¥167)-0.36%▼ (in JPY terms)
Takeda|$42.83 (¥6,848)+0.34%▲ (in JPY terms)
Tokyo Electron|$59.51 (¥9,516)+2.28%▲ (in JPY terms)
Recruit|$109.92 (¥17,575)+5.15%▲ (in JPY terms)
ITOCHU|$15.09 (¥2,413)+0.02%▲ (in JPY terms)
Honda|$11.43 (¥1,828)+0.91%▲ (in JPY terms)
Shin-Etsu|$35.91 (¥5,742)-0.85%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.57%▲ (in JPY terms)
Fast Retailing|$510.40 (¥81,610)+1.77%▲ (in JPY terms)

admin

2026-08-25 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has been launched in the United States as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy.”

by

2026-08-25 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody … 続きを読む

2026-08-25 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated for ASP2138 CLDN18.2-positive, HER2-negative, unresectable locally advanced or metastatic gastric adenocarcinoma and gastroesophageal junction adenocarcinoma.”

by

2026-08-25 Astellas Pharma Inc. “An international collaborative Phase III trial has been initiated for A … 続きを読む

Sister site: Lagrange Financial News (Japanese-language)
Contact